GoodRx (NASDAQ:GDRX) Trading Down 5.1% - What's Next?

Key Points

• GoodRx shares fell 5.1% to about $3.61 in mid-day trading, with volume significantly below the average session level.
• Analyst sentiment remains mixed: the consensus rating is Hold with a $4.16 price target, while TD Cowen and Wells Fargo raised their targets to $5.00 and maintained bullish ratings.
• GoodRx met quarterly earnings expectations at $0.08 per share and exceeded revenue estimates with $200.4 million, though revenue declined 1.3% year over year; institutional investors own 63.77% of the stock.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) traded down 5.1% during mid-day trading on Wednesday . The stock traded as low as $3.60 and last traded at $3.6050. Approximately 459,413 shares were traded during trading, a decline of 78% from the average session volume of 2,102,723 shares. The stock had previously closed at $3.80.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. TD Cowen increased their price objective on shares of GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday. The Goldman Sachs Group reiterated a "neutral" rating and set a $4.00 target price on shares of GoodRx in a research report on Friday, August 7th. Leerink Partners set a $5.00 price target on shares of GoodRx in a report on Thursday, August 6th. Weiss Ratings raised GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday. Finally, Wells Fargo & Company increased their price objective on GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, GoodRx has a consensus rating of "Hold" and a consensus target price of $4.16.

GoodRx Trading Down 4.5%

The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The business has a 50 day moving average of $2.97 and a 200 day moving average of $2.56. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of 90.77, a PEG ratio of 1.69 and a beta of 1.60.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. During the same quarter in the prior year, the firm posted $0.09 earnings per share. The company's quarterly revenue was down 1.3% on a year-over-year basis. As a group, research analysts predict that GoodRx Holdings, Inc. will post 0.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Lazard Asset Management LLC boosted its stake in GoodRx by 43.6% in the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock valued at $85,000 after purchasing an additional 5,201 shares during the period. Brevan Howard Capital Management LP increased its position in GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company's stock worth $404,000 after buying an additional 6,842 shares during the period. Hirtle Callaghan & Co LLC lifted its holdings in shares of GoodRx by 60.3% during the fourth quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company's stock worth $49,000 after buying an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock worth $56,000 after buying an additional 7,580 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of GoodRx in the third quarter valued at about $33,000. Institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source